Mounjaro Injection, Solution
Product Images NDC 50090-8022

Product Visual Gallery

This gallery contains 64 technical images submitted to the FDA as part of the official labeling for Mounjaro (NDC 50090-8022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500908022)

MOUNJARO 12.5 mg/.5 mL injection solution label, containing tirzepatide for subcutaneous use. The label indicates a 30 prefilled pens package from A-S Medication Solutions. Instructions include storage at 86 degrees F, protection from light, and reference to the package insert and medication guide. The product NDC is 50090-8022.*

FDA Label Image

Figure (Logo)

FDA Label Image

Figure (Moun Pen Ifu 1 V3)

MOUNJARO 12.5 mg/0.5 mL injection pen device for subcutaneous use. The pen features a clear cap over the needle cover, a dosage window, and a white body with gray and purple accents. Labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Moun Pen Ifu 10 V2)

An instructional illustration showing a close-up of the gray plunger within a syringe or injection device component for MOUNJARO (tirzepatide) injection, solution, 12.5 mg/0.5 mL, highlighting the plunger as a key part of the device mechanism.*

FDA Label Image

Figure (Moun Pen Ifu 2 V2)

An instructional diagram of the MOUNJARO 12.5 mg/.5 mL subcutaneous injection pen showing labeled parts including a purple injection button at the top, lock ring with indicator, lock or unlock symbol, medicine chamber, clear base, and gray base cap at the needle end.*

FDA Label Image

Figure (Moun Pen Ifu 3 V2)

An illustration of a MOUNJARO (tirzepatide) injection pen showing the location of the expiration date on the device. The expiration date is highlighted with a red circle and arrow pointing to a black label area on the pen.*

FDA Label Image

Figure (Moun Pen Ifu 4a V1)

An instructional illustration showing suggested subcutaneous injection sites for MOUNJARO (tirzepatide). The highlighted areas include the abdomen around the navel and the front upper thighs on both legs.*

FDA Label Image

Figure (Moun Pen Ifu 4b V1)

Illustration showing a human figure from the back, highlighting the upper outer arms area in purple as the recommended site for subcutaneous injection administration.*

FDA Label Image

Figure (Moun Pen Ifu 5 V2)

An instructional illustration showing a hand holding a MOUNJARO 12.5 mg/.5 mL injection pen. The image highlights the clear base of the pen and the removal of the gray base cap, indicated by a downward arrow and labels for both components. A lock symbol is shown near the top part of the pen.*

FDA Label Image

Figure (Moun Pen Ifu 6 V2)

An instructional illustration showing a person administering a subcutaneous injection with a pen device in the abdominal area. The image demonstrates the proper technique for injecting a medication, likely MOUNJARO (tirzepatide) injection, solution, 12.5 mg/0.5 mL.*

FDA Label Image

Figure (Moun Pen Ifu 7 V2)

An instructional illustration showing a hand holding a pen-like injectable device with the cap being twisted off in a circular motion. A lock icon is shown, indicating the unlocking mechanism of the injection device.*

FDA Label Image

Figure (Moun Pen Ifu 8 V2)

An instructional illustration showing a person administering a subcutaneous injection in the abdominal area using an injection device. The image highlights proper hand placement and injection site on the lower abdomen.*

FDA Label Image

Figure (Moun Pen Ifu 9 V2)

An instructional illustration showing a close-up of a syringe tip with a labeled gray plunger inside the transparent barrel. The red arrow points to the gray plunger, highlighting the component within the syringe mechanism.*

FDA Label Image

Figure (Moun Qr)

FDA Label Image

Structural Formula (Moun Uspi Chem Struc)

Chemical structure of tirzepatide, the active ingredient in MOUNJARO injection, solution 12.5 mg/0.5 mL. The structure shows the peptide sequence and molecular components of tirzepatide.*

FDA Label Image

Figure 1 (Moun Uspi F1 V1)

A line graph showing insulin levels (mIU/L) over time in minutes, divided into two phases. The graph compares placebo and tirzepatide 15 mg groups at baseline and week 28, with tirzepatide groups showing increased insulin levels during the second phase, while placebo groups remain relatively constant.*

FDA Label Image

Figure 2 (Moun Uspi F2 V1)

A line graph comparing the HbA1c percentage over weeks post-randomization for MOUNJARO injection at 5 mg, 10 mg, and 15 mg doses versus Semaglutide 1 mg. The x-axis represents weeks post-randomization up to week 40, and the y-axis shows HbA1c percentages ranging approximately from 5.5% to 8.5%. Lines show HbA1c decreasing over time for all doses, with final values near week 40 labeled for each treatment.*

FDA Label Image

Figure (Moun Vial Ifu 1 V1)

Illustration of a MOUNJARO (tirzepatide) injection vial showing the protective cap and the rubber stopper located underneath the cap.*

FDA Label Image

Figure (Moun Vial Ifu 10 V1)

An instructional line drawing depicting a hand holding a vial and a syringe, with an arrow indicating the action of drawing medication from the vial into the syringe. This illustration likely demonstrates how to prepare an injectable drug dose.*

FDA Label Image

Figure (Moun Vial Ifu 11 V1)

An instructional illustration showing hands using a syringe to draw medication from a vial. One hand holds the vial, while the other pulls back the syringe plunger to withdraw the solution. The image demonstrates the proper technique for preparing an injection.*

FDA Label Image

Figure (Moun Vial Ifu 12 V1)

An instructional illustration showing a hand holding a syringe for subcutaneous injection of MOUNJARO (tirzepatide). The syringe is aligned with the injection site on the arm, indicated by a downward arrow. A close-up image of the syringe barrel displays volume markings from 0.0 to 0.6 mL.*

FDA Label Image

Figure (Moun Vial Ifu 13 V1)

An illustration showing two hands holding a syringe and a vial. One hand holds the vial upside down while the other hand pulls back on the syringe plunger, illustrating the process of drawing medication from the vial into the syringe.*

FDA Label Image

Figure (Moun Vial Ifu 14 V1)

An instructional illustration showing a hand holding a vial and drawing solution into a syringe. A close-up inset shows the syringe barrel with volume measurements from 0.1 to 0.5 mL, highlighting the correct fill level at 0.5 mL.*

FDA Label Image

Figure (Moun Vial Ifu 15 V1)

An instructional illustration showing a hand holding a vial and another hand holding a syringe. The syringe is positioned to draw liquid from the vial with an arrow indicating the upward movement of the syringe plunger.*

FDA Label Image

Figure (Moun Vial Ifu 16 V1)

Illustration showing the recommended injection sites for MOUNJARO (tirzepatide) injection, solution. The highlighted areas include the abdomen and the front of the thighs, indicating preferred subcutaneous injection locations.*

FDA Label Image

Figure (Moun Vial Ifu 17 V1)

Illustration showing the recommended injection sites on the upper arms for subcutaneous administration. The diagram displays the back view of a human figure highlighting the outer upper arm areas as suitable locations for injection.*

FDA Label Image

Figure (Moun Vial Ifu 18 V1)

Illustration showing an injection technique for subcutaneous administration. A person holds a syringe with the needle angled towards the abdomen, indicating the site near the waistline for injection.*

FDA Label Image

Figure (Moun Vial Ifu 19 V1)

An instructional illustration showing a person administering a subcutaneous injection in the abdominal area. The hand is holding a syringe angled towards the skin just above the waistband, indicating the injection site.*

FDA Label Image

Figure (Moun Vial Ifu 2 V1)

Diagram of a syringe assembly showing labeled parts: needle shield, needle, syringe body with volume markings in milliliters (ml), plunger tip, and plunger. An enlarged view highlights the 0.5 ml mark on the syringe barrel.*

FDA Label Image

Figure (Moun Vial Ifu 20 V1)

An instructional black-and-white line drawing showing a hand holding a syringe for an injection, positioned near the neck of a person. An arrow points outward from the syringe needle, indicating the direction of injection or removal.*

FDA Label Image

Figure (Moun Vial Ifu 3 V1)

An instructional illustration showing a person removing a protective cap from a small medication vial, likely representing preparation for a subcutaneous injection.*

FDA Label Image

Figure (Moun Vial Ifu 4 V1)

An instructional illustration showing hands removing the protective seal from a small medicine vial or ampule. The image demonstrates the initial step for preparing a subcutaneous injection solution, relevant to the MOUNJARO (tirzepatide) 12.5 mg/0.5mL injection.*

FDA Label Image

Figure (Moun Vial Ifu 5 V1)

An instructional illustration showing hands peeling back the protective strip from an adhesive backing, likely part of applying or preparing a subcutaneous injection device. The image depicts the process of readying a syringe or injector for use.*

FDA Label Image

Figure (Moun Vial Ifu 6 V1)

An instructional illustration showing a person using their hands to peel or remove a protective backing from a small strip or patch, likely related to medication preparation or injection.*

FDA Label Image

Figure (Moun Vial Ifu 7 V1)

An instructional illustration showing a plunger-style syringe with a ribbon wrapped around the barrel and plunger. The image likely depicts an aspect of preparing or handling an injection device.*

FDA Label Image

Figure (Moun Vial Ifu 8 V1)

An instructional illustration showing hands holding a syringe with an arrow pointing left, presumably indicating a step in preparing or handling the injection. The syringe appears partially filled with solution, consistent with the dosage form of MOUNJARO (tirzepatide) injection.*

FDA Label Image

Figure (Moun Vial Ifu 9 V1)

An instructional illustration showing a person holding a syringe with the needle pointing upward. The left portion depicts two hands with an arrow indicating downward motion, while the right portion is a close-up of the syringe barrel showing volume markings from 0.1 to 0.5 mL, with fluid inside near the bottom.*

FDA Label Image

Figure (Moun Vial Md Ifu 14 V1)

An instructional illustration showing a syringe being prepared for injection. One hand holds the syringe body upright while the other hand stabilizes and adjusts the plunger. A close-up inset shows the syringe barrel with volume markings ranging from 0.1 to 0.6 mL. An upward arrow indicates the direction of syringe preparation or plunger movement.*

FDA Label Image

Figure (Moun Vial Md Ifu 2 V1)

An instructional illustration of a prefilled subcutaneous syringe for MOUNJARO 12.5 mg/.5 mL tirzepatide injection. The diagram labels key parts including the needle shield, needle, syringe body with measurement markings from 0.1 to 1.0 mL, plunger tip, and plunger. A magnified view highlights the 0.5 mL dosage mark with the plunger aligned to this level.*

FDA Label Image

Figure (Moun Vial Md Ifu 9 V1)

An instructional illustration showing a hand holding a syringe prepared for injection. The syringe barrel is marked with volume measurements from 0.1 to 0.6 mL. The arrow indicates a downward motion, likely demonstrating how to remove air bubbles or prepare the syringe before administration.*

FDA Label Image

Figure (Mounjaro Kp 1 Pen V1)

The image shows a MOUNJARO 12.5 mg/0.5 mL subcutaneous injection pen device. It features a primarily white body with a light gray grip section and a purple cap on the dosing dial, which displays the number zero. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Mounjaro Kp 10 Dial Clicks V1)

An instructional diagram showing a hand peeling or pulling back a label or sticker from a rectangular object, likely demonstrating part of the preparation or usage process for a product or device.*

FDA Label Image

Figure (Mounjaro Kp 11 Dial Zoom V1)

The packaging label for MOUNJARO 12.5 mg/0.5 mL injection solution for subcutaneous use is shown. The label includes the proprietary name MOUNJARO in large letters, the generic name tirzepatide, and the strength 12.5 mg per 0.5 mL. The labeler is A-S Medication Solutions. The package appears to be a box containing the medication with relevant branding and product information.*

FDA Label Image

Figure (Mounjaro Kp 12 Tap V1)

An illustration showing a hand holding a syringe with another hand pointing towards the syringe plunger. A red arrow indicates a pulling motion of the plunger, suggesting preparation or drawing of medication into the syringe.*

FDA Label Image

Figure (Mounjaro Kp 13 5sec Hold V1)

An instructional illustration showing a hand holding a syringe with an upward arrow above it, indicating the removal of air bubbles. A close-up inset depicts a drop of liquid at the needle tip, alongside a stopwatch icon suggesting timing or waiting during preparation for injection.*

FDA Label Image

Figure (Mounjaro Kp 14 Zero Dial Zoom V1)

MOUNJARO 12.5 mg/0.5 mL injection, solution for subcutaneous use in a glass vial. The label includes the proprietary name, active ingredient tirzepatide, and strength. The labeler is A-S Medication Solutions. The vial has a green plastic cap and a barcode printed on the label.*

FDA Label Image

Figure (Mounjaro Kp 15 Inj Sites V1)

An instructional illustration showing possible subcutaneous injection sites for MOUNJARO (tirzepatide) injection. Highlighted areas include the abdomen, outer thighs, and the back of the upper arms on a front and rear view of a human figure.*

FDA Label Image

Figure (Mounjaro Kp 16 Dial 1 Dose V1)

An instructional illustration showing a hand dialing the dose selector on an injectable pen device. The dial is marked with numbers, and an arrow indicates the direction to turn the dial, with the label 'Dial' beneath the image.*

FDA Label Image

Figure (Mounjaro Kp 17 Dial 1 Zoom V1)

MOUNJARO 12.5 mg/0.5 mL injection, solution in a subcutaneous administration form. The visible packaging label shows the proprietary name MOUNJARO and strength 12.5 mg per 0.5 mL, with the labeler identified as A-S Medication Solutions.*

FDA Label Image

Figure (Mounjaro Kp 18 Insert Needle V1)

An instructional illustration showing the proper technique for injecting a solution subcutaneously. The image depicts a hand holding a syringe at an angle, approaching the skin on the abdomen, with an arrow indicating the direction for injection.*

FDA Label Image

Figure (Mounjaro Kp 19 Push Hold V1)

An instructional illustration showing how to administer a subcutaneous injection using a pen device. It depicts a hand holding the injector pressed against the skin, accompanied by an arrow indicating to push the injector and hold it in place for 5 seconds.*

FDA Label Image

Figure (Mounjaro Kp 2 Pen Parts V2)

An instructional diagram showing the components of the MOUNJARO injection pen for subcutaneous use. It labels parts of the pen including the pen cap with cap clip, cartridge and plunger inside the cartridge holder, pen body with label, dose indicator visible through dose window, and dose knob. Additionally, it details pen needle parts (not included): outer needle shield, inner needle shield, needle, and paper tab. A red inner seal on the cartridge is also highlighted.*

FDA Label Image

Figure (Mounjaro Kp 20 Remove V1)

An instructional diagram showing a hand holding a pen-style injection device near the abdomen, demonstrating the subcutaneous injection technique for MOUNJARO (tirzepatide) 12.5 mg/0.5 mL. A left-pointing arrow indicates the direction for injection administration on the abdominal area.*

FDA Label Image

Figure (Mounjaro Kp 21 Cotton Ball V1)

An instructional illustration showing a person pinching their skin, preparing for a subcutaneous injection. An arrow points to the injection site on the abdomen, indicating proper placement for the injection.*

FDA Label Image

Figure (Mounjaro Kp 22 Recap Shield V1)

An instructional diagram showing a hand holding a pen-like injection device, with an arrow indicating the removal of the device's needle cap prior to use.*

FDA Label Image

Figure (Mounjaro Kp 23 Remove Needle V1)

An instructional illustration showing a hand peeling back the protective foil seal from the end of an injection pen device. The image depicts the removal process of this seal, which covers the pen needle or injection point, with a red arrow highlighting the direction of peeling.*

FDA Label Image

Figure (Mounjaro Kp 24 Recap Pen V1)

An instructional diagram showing a syringe with a protective cap, accompanied by a red arrow pointing to the left indicating the direction to remove the cap from the syringe.*

FDA Label Image

Figure (Mounjaro Kp 3 Wash V1)

An instructional illustration showing two hands with soap bubbles, demonstrating hand washing with lathered soap as part of hygiene or preparation steps.*

FDA Label Image

Figure (Mounjaro Kp 4 Uncap V1)

An instructional illustration showing a subcutaneous injection pen with its cap and an arrow indicating the removal of the cap by pulling it to the left.*

FDA Label Image

Figure (Mounjaro Kp 5 Wipe V1)

Instructional illustration showing two hands removing a cap or seal from the tip of a medication vial or pen. A red arrow indicates the direction to pull the cap off, demonstrating the first step in preparing a subcutaneous injection device for use.*

FDA Label Image

Figure (Mounjaro Kp 6 New Needle Tab V1)

An instructional illustration showing a hand twisting the cap off a small vial or container, indicated by a red curved arrow suggesting the direction to turn. No text is visible to specify the product or details about the process.*

FDA Label Image

Figure (Mounjaro Kp 7 Attach Needle V1)

Instructional illustration showing a step for using an injection pen. It depicts rotating the dose selector knob, indicated by a red curved arrow, likely to set the dose amount for an injectable medication.*

FDA Label Image

Figure (Mounjaro Kp 8 Outer Shield V1)

An instructional diagram showing the removal of a protective cap from a pen-style injection device. The image depicts the cap being pulled straight up and off the device, indicated by a red upward arrow.*

FDA Label Image

Figure (Mounjaro Kp 9 Inner Shield V1)

An instructional diagram showing how to remove the cap from a syringe or injection pen by lifting it upward. The image depicts the cap separated from the syringe with a red upward arrow indicating the direction to pull off the cap.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.